Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis

Supplemental Digital Content is available in the text Aims Patients with cancer are at higher risk of atrial fibrillation, thromboembolic complications and bleeding events compared with the general population. The aim of the present meta-analysis was to compare the efficacy and safety of direct oral Xa inhibitor anticoagulants versus warfarin in patients with cancer and atrial fibrillation. Methods We searched electronic databases for randomized controlled trials comparing direct oral Xa inhibitor anticoagulants and warfarin in cancer patients. The primary efficacy outcome was stroke or systemic embolism. The primary safety outcome was major bleeding. A subgroup analysis was performed to explore the outcome differences between patients with active cancer or history of cancer. Results Three trials with a total of 3029 cancer patients were included in the analysis. There was no statistically significant difference in the risk of stroke or systemic embolism [risk ratio (RR) 0.76; 95% confidence interval (CI) 0.52–1.10] between the two therapeutic strategies. Direct oral Xa inhibitors significantly reduced the incidence of major bleeding compared with warfarin (RR 0.79; 95% CI 0.63–0.99; P = 0.04; number needed to treat = 113). These results were consistent both in patients with active cancer and in those with history of cancer. Conclusion In patients with cancer and atrial fibrillation, direct oral Xa inhibitors have a similar efficacy and may be safer compared with warfarin. These results are consistent both in patients with active cancer and history of cancer.

[1]  L. Zimerman,et al.  Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. , 2020, Cardiology in review.

[2]  M. Ciccarelli,et al.  Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation. , 2019, European heart journal. Cardiovascular pharmacotherapy.

[3]  R. Lopes,et al.  Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. , 2019, European heart journal.

[4]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[5]  Dae Hyun Lee,et al.  Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. , 2019, The American journal of cardiology.

[6]  A. Alexandrov,et al.  Oral anticoagulation in patients with chronic kidney disease , 2019, Neurology.

[7]  R. Giugliano,et al.  Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[8]  G. Boriani,et al.  Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. , 2019, European journal of internal medicine.

[9]  G. Breithardt,et al.  Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF , 2018, European heart journal. Quality of care & clinical outcomes.

[10]  S. de Servi,et al.  Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis. , 2018, International journal of cardiology.

[11]  E. Antman,et al.  Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial , 2018, Journal of the American Heart Association.

[12]  Zachary A. Stacy,et al.  Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations , 2018, Therapeutic advances in cardiovascular disease.

[13]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[14]  C. Torp-Pedersen,et al.  CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer , 2018, European journal of preventive cardiology.

[15]  J. Uhm,et al.  Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer , 2018, Korean circulation journal.

[16]  N. Fortunati,et al.  Cancer survivors: An expanding population with an increased cardiometabolic risk. , 2018, Diabetes research and clinical practice.

[17]  L. Chen,et al.  Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. , 2018, Blood advances.

[18]  S. Gruber,et al.  Association of atrial fibrillation and cancer: Analysis from two large population-based case-control studies , 2018, PloS one.

[19]  P. Golino,et al.  Use of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review , 2017, Seminars in Thrombosis and Hemostasis.

[20]  H. Heidbuchel,et al.  The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. , 2017, Arrhythmia & electrophysiology review.

[21]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  Jeroen J. Bax,et al.  Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[23]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[24]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[25]  A. Khorana,et al.  Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation. , 2017, The American journal of cardiology.

[26]  A. Dunning,et al.  Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. , 2017, The American journal of medicine.

[27]  H. Kamel,et al.  Risk of Arterial Thromboembolism in Patients With Cancer. , 2017, Journal of the American College of Cardiology.

[28]  J. Wills,et al.  Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. , 2016, The American journal of cardiology.

[29]  E. Lippert,et al.  Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms , 2017, International Journal of Hematology.

[30]  E. Horváth-Puhó,et al.  Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population‐based cohort study , 2017, Cancer medicine.

[31]  G. Andò,et al.  Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. , 2017, International journal of cardiology.

[32]  Guilherme H M Oliveira,et al.  Atrial Fibrillation and Cancer-Validation in the Real World. , 2016, JAMA cardiology.

[33]  Jeroen J. Bax,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines , 2016, European journal of heart failure.

[34]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[35]  N. Cook,et al.  Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. , 2016, JAMA cardiology.

[36]  J. Uhm,et al.  Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. , 2016, International journal of cardiology.

[37]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[38]  T. Chao,et al.  Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. , 2013, International journal of cardiology.

[39]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[40]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[41]  E. Hylek,et al.  Effectiveness of Warfarin among Patients with Cancer , 2007, Journal of General Internal Medicine.

[42]  M Gent,et al.  Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.